Literature DB >> 35141870

Using menopausal hormone therapy after a cancer diagnosis in Ireland.

Fionán Donohoe1, Yvonne O'Meara2, Aidin Roberts2, Louise Comerford2, Catherine M Kelly3, Janice M Walshe4, Deirdre Lundy5, Martha Hickey6, Donal J Brennan2,7.   

Abstract

BACKGROUND: Menopause may cause a constellation of symptoms that affect quality of life. Many women will have menopause induced or exacerbated by treatment for cancer whether that be through surgery, chemotherapy, radiotherapy, or anti-endocrine therapy. As treatments advance, the number of people living with and beyond a cancer diagnosis is set to increase over the coming years meaning more people will be dealing with the after effects of cancer and its treatment. AIMS: This review aims to summarise available data to guide clinicians treating women with menopausal symptoms after the common cancer diagnoses encountered in Ireland. The use of menopausal hormone therapy is discussed as well as non-hormonal and non-pharmacological options.
CONCLUSIONS: Managing menopausal symptoms is an important consideration for all physicians involved in the care of people living with and beyond a cancer diagnosis. High-quality data may not be available to guide treatment decisions, and, thus, it is essential to take into account the impact of the symptoms on quality of life as well as the likelihood of recurrence in each individual case.
© 2022. The Author(s).

Entities:  

Keywords:  Cancer; Menopause; Survivorship

Year:  2022        PMID: 35141870     DOI: 10.1007/s11845-022-02947-6

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  83 in total

Review 1.  Premature menopause or early menopause: long-term health consequences.

Authors:  Lynne T Shuster; Deborah J Rhodes; Bobbie S Gostout; Brandon R Grossardt; Walter A Rocca
Journal:  Maturitas       Date:  2009-09-05       Impact factor: 4.342

2.  BMS - Consensus statement.

Authors:  Joan Pitkin
Journal:  Post Reprod Health       Date:  2018-09

Review 3.  Managing the menopause: An update.

Authors:  Helen Roberts; Martha Hickey
Journal:  Maturitas       Date:  2016-01-22       Impact factor: 4.342

Review 4.  Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.

Authors:  P-Y Scarabin
Journal:  Climacteric       Date:  2018-03-23       Impact factor: 3.005

5.  Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.

Authors:  Agnès Fournier; Sylvie Mesrine; Laure Dossus; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Nathalie Chabbert-Buffet
Journal:  Breast Cancer Res Treat       Date:  2014-04-30       Impact factor: 4.872

6.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.

Authors:  Agnès Fournier; Franco Berrino; Françoise Clavel-Chapelon
Journal:  Breast Cancer Res Treat       Date:  2007-02-27       Impact factor: 4.872

7.  Adenocarcinoma of the endometrium in women 40 years of age or younger.

Authors:  D G Gallup; R J Stock
Journal:  Obstet Gynecol       Date:  1984-09       Impact factor: 7.661

8.  Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.

Authors:  Marianne Canonico; Agnès Fournier; Laure Carcaillon; Valérie Olié; Geneviève Plu-Bureau; Emmanuel Oger; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Pierre-Yves Scarabin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

9.  The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women.

Authors:  Haitham Hamoda; Nick Panay; Hugo Pedder; Roopen Arya; Mike Savvas
Journal:  Post Reprod Health       Date:  2020-10-12

10.  Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Authors:  Agnès Fournier; Alban Fabre; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Franco Berrino; Françoise Clavel-Chapelon
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.